[go: up one dir, main page]

PE20011232A1 - CRYSTALLINE FORMS OF LOPINAVIR - Google Patents

CRYSTALLINE FORMS OF LOPINAVIR

Info

Publication number
PE20011232A1
PE20011232A1 PE2001000299A PE2001000299A PE20011232A1 PE 20011232 A1 PE20011232 A1 PE 20011232A1 PE 2001000299 A PE2001000299 A PE 2001000299A PE 2001000299 A PE2001000299 A PE 2001000299A PE 20011232 A1 PE20011232 A1 PE 20011232A1
Authority
PE
Peru
Prior art keywords
lopinavir
crystalline forms
amin
dimethylphenoxiacetyl
tetrahydropyrimid
Prior art date
Application number
PE2001000299A
Other languages
Spanish (es)
Inventor
Daniel A Dickman
Sanjay Chemburkar
Rodger F Henry
Yuping Niu
William Porter
David Lechuga-Ballesteros
James J Fort
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20011232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PE20011232A1 publication Critical patent/PE20011232A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A LA FORMA CRISTALINA HIDRATADA O SOLVATADA DE LOPINAVIR (2S,3S,5S)-2-(2,6-DIMETILFENOXIACETIL)AMIN-3-HIDROXI-5-(2-(1-TETRAHIDROPIRIMID-2-ONIL)-3-METILBUTANOL)AMIN-1,6-DIFENILHEXANO) DE FORMULA I CARACTERIZADA POR PRESENTAR UN ESPECTRO INFRARROJO; UN PATRON DE DIFRACCION DE RAYOS X. EL LOPINAVIR ES UN INHIBIDOR DE PROTEASA DEL VIHREFERS TO THE HYDRATED OR SOLVATED CRYSTALLINE FORM OF LOPINAVIR (2S, 3S, 5S) -2- (2,6-DIMETHYLPHENOXIACETYL) AMIN-3-HYDROXY-5- (2- (1-TETRAHYDROPYRIMID-2-ONYL) -3 -METHYLBUTANOL) AMIN-1,6-DIPHENYLHEXANE) OF FORMULA I CHARACTERIZED BY PRESENTING AN INFRARED SPECTRUM; AN X-RAY DIFFRACTION PATTERN. LOPINAVIR IS AN INHIBITOR OF HIV PROTEASE

PE2001000299A 2000-03-30 2001-03-30 CRYSTALLINE FORMS OF LOPINAVIR PE20011232A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical

Publications (1)

Publication Number Publication Date
PE20011232A1 true PE20011232A1 (en) 2001-12-08

Family

ID=27065762

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000299A PE20011232A1 (en) 2000-03-30 2001-03-30 CRYSTALLINE FORMS OF LOPINAVIR

Country Status (22)

Country Link
EP (1) EP1268442A2 (en)
JP (1) JP2003529592A (en)
KR (1) KR100773258B1 (en)
CN (2) CN1330639C (en)
AR (2) AR033360A1 (en)
AU (3) AU5092001A (en)
BG (1) BG107165A (en)
BR (1) BR0109433A (en)
CA (1) CA2403635A1 (en)
CZ (1) CZ20023529A3 (en)
HU (1) HUP0302675A3 (en)
IL (1) IL151551A0 (en)
MX (1) MXPA02009559A (en)
MY (1) MY128296A (en)
NO (1) NO325005B1 (en)
NZ (1) NZ521183A (en)
PE (1) PE20011232A1 (en)
PL (1) PL359727A1 (en)
SA (2) SA01220270B1 (en)
SK (1) SK14832002A3 (en)
TW (1) TWI284640B (en)
WO (1) WO2001074787A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8445506B2 (en) 2009-02-06 2013-05-21 Hetero Research Foundation Polymorphs of lopinavir
EP2470189A4 (en) * 2009-08-27 2013-01-23 Merck Sharp & Dohme METHODS FOR PREPARING HEPATITIS C VIRUS PROTEASE INHIBITORS
CN112830899A (en) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 Novel lopinavir crystal form and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
NO325005B1 (en) 2008-01-14
AR033360A1 (en) 2003-12-17
CN1330639C (en) 2007-08-08
TWI284640B (en) 2007-08-01
AU5092001A (en) 2001-10-15
AR049560A2 (en) 2006-08-16
AU2001250920B2 (en) 2006-06-29
CN1422259A (en) 2003-06-04
MXPA02009559A (en) 2003-05-21
KR20030011807A (en) 2003-02-11
BG107165A (en) 2003-07-31
WO2001074787A3 (en) 2002-02-07
WO2001074787A2 (en) 2001-10-11
SA06270303B1 (en) 2009-08-02
HUP0302675A3 (en) 2004-03-29
PL359727A1 (en) 2004-09-06
JP2003529592A (en) 2003-10-07
HUP0302675A2 (en) 2003-12-29
MY128296A (en) 2007-01-31
NO20024679D0 (en) 2002-09-30
IL151551A0 (en) 2003-04-10
CZ20023529A3 (en) 2003-02-12
CA2403635A1 (en) 2001-10-11
EP1268442A2 (en) 2003-01-02
NO20024679L (en) 2002-09-30
BR0109433A (en) 2004-08-10
CN101066952A (en) 2007-11-07
SK14832002A3 (en) 2003-02-04
SA01220270B1 (en) 2006-11-14
NZ521183A (en) 2004-03-26
KR100773258B1 (en) 2007-11-05
AU2006222711A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
CY1113508T1 (en) 2,4-DIAMINOPYRIMIDINE PRODUCT
SE0100902D0 (en) Compounds
NO950533L (en) Hydroxyethylaminosulfonamides useful as retroviral protease inhibitors
AR051778A2 (en) DERIVATIVES OF DIMETHYLAMINOCROTONIC ACID AND PROCESSES FOR SUPREPARATION
CY1113578T1 (en) 2,3-dihydro-6-nitroimidazo 2,1-B-oxazolia
MY129188A (en) Metalloproteinase inhibitors
NO20045150L (en) Cellular accumulation of phosphonate analogues for HIV protease inhibitor compounds and the compounds as such
ATE506354T1 (en) SUBSTITUTED ARYLCYCLOPROPYLACETAMIDE AS GLUCOCINASE ACTIVATORS
CY1113657T1 (en) NEW PRODUCERS OF BENZOFFAINE OR SALTS
MA27643A1 (en) USE OF N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES AS ANTIMICROBIAL AGENTS
ECSP045221A (en) SALTS OF VALSARTAN
DK1385515T3 (en) Spiropyrazole compounds
PH12022553498A1 (en) Novel acid secretion inhibitor and use thereof
EA200200819A1 (en) CRYSTAL FORM II LINEZOLIDE
ATE452889T1 (en) SULFONAMIDES INHIBITING THE HIV PROTEASE
ATE368645T1 (en) AMINO ACID DERIVATIVES AS HIV PROTEASE INHIBITORS
ATE382604T1 (en) AMINO ACID DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS
SE0103710D0 (en) Compounds
ATE352555T1 (en) PERINDOPRIL
PE20011232A1 (en) CRYSTALLINE FORMS OF LOPINAVIR
PA8543701A1 (en) PHENYL-HETEROCICLIL-ETERES
BR0114156A (en) Amorphous form of cell cycle inhibitor
EA200801365A1 (en) SUBSTITUTED 5-PHENYL-3,6-DIGIDRO-2-OXO-6H-1,3,4-TIADIAZINS
UY26416A1 (en) COMPOUNDS
MXPA04004020A (en) Substituted thien-3-yl-sulfonylamino(thio)carbonyl-triazolin(thi)ones.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal